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Background: The malaria caused by Plasmodium falciparum remains a serious public health problem in the world,
due largely to the absence of an effective vaccine. There is a lack of information on the structural properties and
antigens capable of activating the immunological mechanisms for the induction of protective immunity. Therefore,
the objective of this study is to evaluate the serological reactivity of sera from individuals with imported malaria
and identify major immunogenic proteins.
Methods: The study was conducted in 227 individuals with imported malaria and 23 healthy individuals who had
never been in areas endemic for malaria. The determination of anti-P. falciparum IgG antibodies was performed by
an ELISA validated and optimized for this study. Sera showing higher reactivity to anti-P. falciparum by ELISA were
analysed by immunoblotting and immunogenic proteins were identified by mass spectroscopy.
Results: The results of anti-P. falciparum antibodies research by ELISA indicates 78 positive, 137 negative and 12
indeterminate sera. Analysis of immunoblotting demonstrated a consistent pattern with respect to
immunoreactivity of antigens with molecular weights in the range of 40 to 60 kDa. Between 40 and 60 kDa six
immunogenic proteins were identified: elongation factor-1 alpha (EF-1α), protein disulphide isomerase (PDI);
phosphoglycerate kinase (PGK); 78 kDa glucose-regulated protein homologue (GRP-78); rhoptry-associated protein 2
(RAP-2) and rhoptry-associated protein 3 (RAP-3).
Conclusions: It was identified immunogenic proteins essential for parasite survival in the host, two of which (RAP-2
and RAP-3) are already described in the literature as proteins that play an important role in the invasion of
erythrocytes by extracellular merozoites.
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Malaria is an infectious disease caused by unicellular,
obligate, intracellular, protozoan parasites belonging to
the genus Plasmodium and the main form of transmis-
sion is through the bite of the female Anopheles
mosquito. There are over 200 species in the genus Plas-
modium, but only five species of malaria parasites infect
humans: Plasmodium falciparum, Plasmodium ovale,
Plasmodium malariae, Plasmodium vivax and Plasmo-
dium knowlesi. Plasmodium falciparum is the most* Correspondence: mssilva@ihmt.unl.pt
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reproduction in any medium, provided the orvirulent of the human malaria parasites: it can cause
severe malaria, a complication that is often fatal and is
responsible for the bulk of the malaria-related mortality,
particularly in African infants [1].
Malaria is currently endemic in the tropical zones with
extensions into the subtropical regions of Asia, Africa,
South and Central America. According to the 2011
World Malaria Report, there were an estimated 216
million episodes of malaria and 655,000 worldwide
malaria deaths in 2010, 91% of which were in Africa [2].
Approximately 86% of malaria deaths globally were
children less than five years of age from sub-Saharan
Africa [2].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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problems not only in endemic countries but also in non-
endemic areas where the increasing number of imported
malaria cases is worrying [3]. In developed countries,
imported malaria predominates in tourists and immi-
grants. Every year, approximately 125 million international
travellers visit malaria-endemic areas and 30,000 of them
contract the disease [4,5]. Portugal maintains a close
relationship with its former colonies for several reasons
and so malaria must be suspected in travellers that
return from those countries. Malaria is a notifiable
disease in Portugal and about 50 cases are reported
annually to the National Public Health System [4,6].
Non-immune people (from non-endemic countries)
who stay for some time in malaria-affected areas are at
increased risk of having severe forms of the disease and
can develop symptoms of P. falciparum malaria within
a month after leaving the endemic area [7]. In non-
endemic countries for malaria, the diagnosis and
adequate treatment is delayed due to the fact that
malaria is infrequent in these countries, which can
make these cases fatal to patients.
The life cycle of malaria parasites is complex. The
invasion of erythrocytes by Plasmodium merozoites is a
multistep process of specific protein interactions be-
tween the parasite and the red blood cell. The first step
is the initial recognition and reversible merozoite attach-
ment to the erythrocyte followed by its apical reorienta-
tion, irreversible junction formation between the apical
end of the merozoites and finally entry into the red cell
in a parasitophorous vacuole. This stage of the life cycle
is regarded as an attractive target for the development of
interventions to combat malaria since the invasion of
erythrocytes by the merozoites requires specialized
protein expression, such as merozoite surface protein 1
(MSP-1) and a series of highly specific molecular
interactions.
The emergence of resistant strains of the parasite, the
spread of mosquito strains resistant to insecticides and
lack of effective vaccines against malaria are the main
factors hampering the fight against the disease. Given
the limited exposure of these proteins to the immune
system of the host, the antibodies are likely to be the
main form of immunity against merozoites [8]. Epi-
demiological and experimental evidence has revealed the
crucial importance of antibody-mediated effector mech-
anisms directed predominantly at antigens of blood
stage parasites [9]. In a similar study, gamma globulin of
adults in West Africa was administered to individuals of
East Africa with serious infections by P. falciparum, which
led to the abrupt reduction of parasite density and recov-
ery of clinical disease [10]. In Thai patients, the protective
effect of IgG antibodies against African P. falciparum was
also demonstrated by passive transfer [11], and antibodiesto immune African individuals are capable of controlling
the erythrocytic stage of the parasite in Saimiri monkeys
[12]. To date, the exact mechanism of protection, whereby
the malaria-specific antibodies interfere with the develop-
ment and/or proliferation of asexual stages of P. falcip-
arum, is still not accurately known, and the antigens
targeted by protective antibodies remain a topic for
discussion.
Immunization with antigens of the erythrocytic phase,
particularly antigens from merozoites, has been shown
to be protective in various animal models and to have
some protective effect in humans [13]. Studies in human
and in animal models have shown that the immune
response directed to erythrocytic stage antigens may be
protective and facilitate the control of infection [14]. It
is known that in endemic areas naturally IgG antibodies
mediate acquired immunity against P. falciparum.
Despite the global importance of P. falciparum, most
of their proteins have not been yet characterized experi-
mentally. Therefore, the main objective of this study is
to evaluate the serological reactivity of serum samples
from individuals, mainly from African countries, who
have potentially been exposed to P. falciparum, com-
pared to native parasite antigens and subsequent identi-
fication of major immunogenic proteins.
Methods
Study population
Sera recruited for this study of patients with imported
malaria, as well as negative sera (healthy Portuguese
individuals who have never been in malaria-endemic
countries) were obtained at the Clinical Unit for Trop-
ical Diseases (IHMT, Portugal).
The population for this study consisted of 227 individ-
uals with imported malaria and 23 healthy individuals
(residents in Portugal). Most are adults who were in differ-
ent endemic regions of Africa, including Angola, Guinea,
Mozambique, Sao Tome, Cape Verde, Madagascar, Gabon,
Congo, Tanzania and Morocco. Some sera were from indi-
viduals who had been in Brazil, Ecuador, India, Indonesia,
Thailand and Haiti. As a negative control, a group of 23
sera from healthy Portuguese individuals, who had never
been in endemic countries, was used.
Consent
The institutional Ethics Committee at the Instituto de
Higiene e Medicina Tropical, Lisbon, Portugal, approved
this study protocol. Written informed consent was obtained
from the patient for serological assays for malaria and pub-
lication for this manuscript (Additional files 1 and 2).
Cultured parasites
3D7 P. falciparum clones were cultured at 5% haemato-
crit, 37°C and atmosphere with 5% of CO2 as described
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AlbuMAXII (Invitrogen ™) in the culture medium. When
parasitaemia reached about 8-10%, cultures were harvested
for parasite protein extraction.
For the extraction of total proteins of P. falciparum cul-
tures were centrifuged at 5,000 rpm for five minutes at
room temperature, and the supernatant was discarded.
Pellet was washed with PBS once, resuspended in equal
volume of PBS and a solution of saponin 0.5% in PBS and
incubated for 10 minutes at 4°C. Subsequently the mixture
was centrifuged at 10,000 rpm at 4°C for 10 minutes, the
supernatant discarded and parasites washed three times
with ice-cold PBS. For the extraction of all proteins of the
parasite lysis buffer was added (0.5% NP-40, 120 mM NaCl,
50 mM Tris–HCl pH 7.8), homogenized thoroughly in the
vortex and centrifuged for 15 minutes at 10,000 rpm at 5°C.
The supernatant was recovered, discarding the haemozoin.
Proteins were quantified by the Bradford method.
Determination of anti-Plasmodium falciparum antibodies
It was used the total protein of P. falciparum antigen for
the search of IgG antibodies in serum from patients with
imported malaria. Briefly, 96-well microplates (BD
FALCONTM - EUA) were coated with 100 ng/well of the
antigen diluted in bicarbonate buffer (0.1 M, pH 8.5),
overnight at 4°C. All ELISAs were carried out using a
100 μL reaction mixture volume. After incubation, the
plates were washed three times with 200 μL of wash
buffer (PBS containing 0.05% Tween 20) per well and
the wells were blocked with 5% low-fat milk in PBS
(pH 7.2) for one hour at room temperature with orbital
stirring. Plates were washed three times with 200 μL/
well with wash buffer. Then the plates were incubated
with 100 μL/well of diluted sera, for one hour at room
temperature with orbital stirring. After incubation with
serum samples, the plate was washed five times with 200
μL of wash buffer. For detection of human anti-P. falcip-
arum antibodies, the plate was incubated with 100 μL/well
of anti-human horseradish peroxidase (HRP)-conjugated
IgG secondary antibody (Sigma-USA) for one hour at
room temperature with orbital agitation. Then, five wash-
ings were made, each with 200 μL/well of wash buffer. To
reveal the presence of conjugate the plate was incubated
with 100 μL/well of substrate solution (10 mL citrate
buffer pH 5.0 with 10 mg OPD, and 10 μL of hydrogen
peroxide 30% v/v), for 30 minutes at room temperature
and protected from light. To stop the reaction, it was used
4.0 N sulphuric acid. The cut-off value was defined as a
mean of OD from negative control, plus twice standard
deviation (Cut-off =m + 2SD).
Protein characterization and immunoblotting
Plasmodium falciparum proteins were separated by SDS-
PAGE with a 12% polyacrylamide gel. The determinationof the protein’s molecular mass was estimated by compari-
son with a commercial HyperPAGEW (Bioline, UK)
molecular weight marker. After SDS-PAGE, the gel was
withdrawn from the cassette and the gel was equilibrated
in transfer buffer for 20 minutes to remove the excess
SDS. The membrane and the filter paper used for transfer
were equilibrated in transfer buffer for 10 minutes. The
antigenic proteins were transferred to a PVDF membrane,
previously activated in methanol for five seconds.
The electroblotting was performed in a semi-dry
system (BIO-RAD, USA) at 15 V for 15 minutes. After
transfer of proteins from the gel to the membrane, the
membrane was washed twice with 15 mL of PBS for 10 -
minutes each. This was followed by blocking of the
membrane with 15 mL blocking solution (3% BSA w/v
in PBS buffer) for one hour at room temperature. To
remove the excess BSA, the membrane is washed three
times, twice with 20 mL PBS-0.5% Tween for 10 minutes
each, and once with 15 mL of PBS for 10 minutes. For
immunodetection of antigens on the membrane were
used serum samples from patients with higher reactivity
observed by ELISA (n = 32). As negative controls, it was
used sera from patients who had never been in contact
with the parasite or in malaria-endemic areas. This was
followed by incubating the membrane with 10 mL of
primary antibody (1:1,000 in blocking solution) for one
hour at room temperature with orbital agitation. After
incubation with primary antibodies the membrane was
washed three times, twice with 20 ml of PBS-0.5%
Tween for 10 minutes each, and once with 15 mL of
PBS for 10 minutes. For detection of the antibody-
antigen complex the membrane was incubated with
8 mL of secondary antibody anti-IgG-HRP (Sigma-USA)
diluted 1:6,000 in blocking solution for one hour at
room temperature with orbital agitation. After the incu-
bation period, the membrane was washed five times with
20 mL PBS-0.5% Tween for 10 minutes each. To reveal
the presence of the conjugate the membrane is incu-
bated with 15 mL of developing solution (7.5 mg
diaminobenzidine in PBS with 0.02% H2O2) at room
temperature until colour development. The reaction was
quenched with 20 mL of distilled water. After stopping
the reaction membrane was dried and stored for later
use in the identification of immunogenic proteins by
mass spectroscopy.
Protein identification by mass spectrometry
Protein bands were excised manually from the SDS-PAGE
gel distained with 25 mM ammonium bicarbonate/50%
acetonitrile and dried under vacuum (SpeedVacW, Thermo
Savant, USA).
The dried gel pieces were rehydrated with 25μL of
10 μg/mL trypsin (Promega, USA) in 50 mM ammo-
nium bicarbonate and digested overnight at 37°C.
Figure 1 Results of the study of reactivity of sera from patients
with acute imported malaria by anti-Plasmodium falciparum
ELISA. A - IgG specific antibodies were searched within a total of
227 sera. Positive n = 78; negative n = 137 and indeterminate n = 12.
B – Zoom in on O.D/Cut-off ratio = 1.
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formic acid/50% acetonitrile and dried in a vacuum con-
centrator, resuspended in 10μL of a 50% acetonitrile/
0.1% formic acid solution and mixed (1:1) with a matrix
consisting of a-cyano-4-hydroxycinnamic acid. Aliquots
of samples were spotted onto the MALDI sample target
plate. Mass analysis of peptides of each sample was
performed with a 4800 MALDI-TOF/TOF Analyzer
(ABSciex) in automatic mode with the following settings:
for the MS data, m/z range 800 to 4,500 with an acceler-
ating voltage of 20 kV and delayed extraction, peak density
of maximum 50 peaks per 200 Da, minimal S/N ratio of
10 and maximum peak at 65. Spectra were internally cali-
brated with peptides from trypsin autolysis (M+H+ =
842.509, M +H+ = 2211.104).
For the MS/MS data, fragment selection criteria were
a minimum S/N ratio of 6, a maximum number of peaks
set at 65 and peak density of maximum 50 peaks per
200 Da. For each precursor selected for MS/MS analysis,
fragment mass values in the range from 60 Da to 10 Da
below precursor mass were used to peptide identifica-
tion. Protein identification was assigned by peptide mass
fingerprinting and confirmed by MS/MS analysis.
Mascot (v2.1, Matrixscience) was used for protein identifi-
cation running on GPS software (Applied Biosystems).
Searches were performed against the NCBi (October2011)
under all taxonomic categories and the following parame-
ters: (i) two missed cleavages by trypsin; (ii) mass toler-
ance of precursor ions 25 ppm and product ions 0.3 Da;
(iii) carboxymethylated cysteines; and, (iv) oxidation of
methionine as variable modification. Protein identifica-
tions were considered as reliable when the individual ion
score for each peptide had a minimum individual score of
95% and a minimum sequence tag of four amino acids
(five consecutive peaks in the MS/MS spectrum).
Results
In this study, an anti-P. falciparum immunoassay
(ELISA) was validated and optimized to distinguish the
more reactive sera with regard to the presence of specific
anti-P. falciparum IgG antibodies in human serum sam-
ples. All sera of patients with imported malaria were
analysed for antibodies of the IgG type, at a dilution of
1:40,000. These patients were actively recruited in the
Clinical Unit for Tropical Diseases (IHMT, Portugal).
To differentiate positive from negative sera a limit
point (cut-off ) was defined. To determine the cut-off
value it was used the 23 sera from healthy Portuguese
individuals (control group) who had never been in
malaria-endemic areas. The cut-off value was defined as
a mean of OD from negative control, plus two standard
deviation (cut-off = m + 2SD); at a dilution of 1:40,000.
The weight that the standard deviation (SD) may have
on the cut-off value depends on the sensitivity andspecificity of this cut-off value will give the method [17].
This was chosen weighting (2SD) because with this cut-
off value all negative sera have an absorbance value less
than or equal to the cut-off value chosen for dilution.
For the analysis of the results, it was used as discern-
ible criteria the ratio between the absorbance/cut-off; all
sera with this ratio above 1.1 were considered positive
for anti-P. falciparum antibodies (Figure 1). Apart from
these groups, another group was set up, the indetermin-
ate group, which were all sera with a value of absorbance
within a range of cut-off ± 10% of cut-off value. The
results of anti-P. falciparum antibodies research by
ELISA indicates 78 positive, 137 negative and 12 indeter-
minate sera.
Through fractionation of antigens of P. falciparum
identified by SDS-PAGE associated with the immuno-
blotting technique, it was identified specific components
of parasite that may be associated with acute infection,
since the tested sera were from patients with imported
acute malaria.
Analysis of immunoblotting profiles of the 32 most
reactive sera by ELISA demonstrated a consistent pat-
tern with respect to immunoreactivity of antigens with
molecular weights in the range of 40 to 60 kDa
(Figure 2). Between 40 and 60 kDa, was identified four
main bands in the membranes that were analysed by
mass spectrometry (Figure 3 and Additional file 3) and it
was identified six immunogenic proteins: elongation
factor-1 alpha (EF-1α), protein disulphide isomerase (PDI);
phosphoglycerate kinase (PGK); 78 kDa glucose-regulated
protein homologue (GRP-78); rhoptry-associated pro-
tein 2 (RAP 2) and rhoptry-associated protein 3 (RAP 3)
(Additional file 3).
Figure 2 Immunoblotting profiles of the reactive sera by anti-Plasmodium falciparum ELISA. Each strip contains approximately 14 μg of
P. falciparum. M - Molecular mass marker Hyper PAGEW, N - negative control sera.
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In order to achieve the proposed objectives, it was
initially cultivated the parasite P. falciparum (3D7) in an
in vitro system of red blood cells (RBCs), followed by
the extraction of total native proteins from the parasiteFigure 3 Result of protein identification by mass spectrometry.
Six proteins were identified from a previous SDS-PAGE. F1 -
elongation factor-1 alpha (EF-1α), protein disulphide isomerase (PDI);
phosphoglycerate kinase (PGK); 78 kDa glucose-regulated protein
homologue (GRP-78); rhoptry-associated protein 2 (RAP 2) and
rhoptry-associated protein 3 (RAP 3).and its quantification by the Bradford method. It was
also used enzyme immunoassays (ELISA) to distinguish
a serologically negative from a positive population, com-
pared to a control group of healthy individuals (n = 23)
from Portugal, who had never been in areas that are
endemic to malaria. Sera displaying greater reactivity to
anti-P. falciparum antibodies by ELISA were analysed by
immunoblotting. The analysis of the blots profiles dem-
onstrated a consistent pattern with respect to the immu-
noreactivity of antigens with molecular weights ranging
from 40 to 60 kDa (Figure 2).
The life cycle of P. falciparum is complex since its na-
ture requires expression of multiple specialized proteins
necessary for the invasion of different types of cells as well
as to survive in both invertebrate (mosquito) and verte-
brate (human) host organisms [18]. Due to the complexity
of the life cycle, each life stage expresses a number of anti-
genic proteins that can induce an immune response and
which presents a real challenge for vaccine design [19].
It was observed that the immunoreactivity of the sera
from patients potentially exposed to P. falciparum corre-
sponds to some of the antigens prevalent in total protein
extracts from parasites and six immunogenic proteins
were identified by mass spectrometry (Figure 3 and
Additional file 3): elongation factor-1 alpha (EF-1α); pro-
tein disulphide isomerase (PDI); phosphoglycerate kinase
(PGK); 78 kDa glucose-regulated protein homologue
(GRP-78), rhoptry-associated protein 2 (RAP-2) and
rhoptry-associated protein 3 (RAP-3).
Eukaryotic elongation factor 1A (eEF1A) plays a central
role in protein synthesis, cell growth and morphology
[20,21]. Malaria parasite possesses two identical genes
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pbeef1a P. berghei mutants that lack an eEF1a gene show
that the level of eEF1A production affects the proliferation
of blood stages and parasite fitness [21]. Further attenu-
ation of parasites through elongation of the cell cycle by
affecting protein synthesis machinery, might be used for
testing the feasibility of the creation of attenuated live par-
asites as vaccine [21].
Proteins disulfide isomerases (PDI) are a family of redox
chaperones that are implicated in protein unfolding and
trafficking across the endoplasmic reticulum (ER) and
towards the cytosol, a thiol-based redox locus for antigen
processing [22].
The major pathway for glucose metabolism in P.
falciparum-infected RBCs is anaerobic glycolysis. PGK is
one of the key enzymes of this pathway as it generates
ATP [23]. The GRP-78 is a heat shock-related protein
and may play a role in the adaptation of parasites during
their complex life cycle [24]. The stages of the parasite
that grow and multiply in RBCs cause all the pathological
effects and accordingly the invasion of RBCs is one of the
most important steps in the parasite life cycle.
The rhoptries are specialized secretory organelles
located at the apical end of merozoites, the form of the
parasite that invades RBCs. Its contents include proteins
that have been implicated as having a role in the inva-
sion process such as RAP-2 and RAP-3 [25,26]. RAP-1
controls RAP-2 or RAP-3 transport toward the rhoptries
during invasion, when the gene encoding RAP-1 is
interrupted, the traffic of either of the other two proteins
is affected and such proteins remain trapped in the
endoplasmatic reticule. Invasion does not become
inhibited when the gene encoding RAP-3 is interrupted
but does become reduced to some degree. These obser-
vations suggest that the loss of RAP-3 is compensated
for by the presence of RAP-2 and vice-versa. Several
studies have demonstrated the importance of responses
mediated by antibodies to rhoptry proteins in protection
against malaria. In vitro studies showed that monoclonal
antibodies directed against RAP-2 provide substantial in-
hibition of merozoites in invasion of RBCs [27]. Experi-
mental evidence demonstrated that RAP-2 is a ligand used
by merozoites to invade RBCs. This protein has four RBC
binding sequences defined by high-activity binding pep-
tides (HABPs) 26220 (61NHFSSADELIKYLEKTNINT80)
and 26225 (161IKKNPFLRVLNKASTTTHAT180) in the
protein’s amino terminal and central parts and HABPs
26229 (241RSVNNVISKNKTLGLRKRSS260) and 26235
(361FLAEDFVELFDVTMDCYSRQ380) in the carboxyl
terminal region [25]. All HABPs bind to a 62-kDa pro-
tein located on the RBCs surface. HABPs 26225 and
26229 also bind to the 42-kDa RBC proteins.
Additionally, RAP-3 can act as an auxiliary protein in
the RAP complex in maintaining the cycle during bloodstage. Invasion does not become inhibited when the
gene encoding RAP-3 is interrupted but does become
reduced to a certain extent. RAP-3 shows two HABPs:
33860 (61FNHFSNVDEAIEYLKGLNIN80) and 33873
(321KNRTYALPKVKGFRFLKQLF340) [25].
Rhoptry-associated proteins may be used as targets for
multi-antigen, multistage, subunit-based, anti-malarial
vaccine development. A completely effective vaccine has
not yet been developed against this disease, mainly due
to the incomplete knowledge of the intimate molecular
interactions between parasite proteins and their specific
host cell membrane receptor(s) during invasion. The
proteins identified in this study may be the starting point
for more detailed studies regarding control strategies
and disease prevention.
Conclusions
In this study, analysis of immunoblotting profiles of
serological reactive sera from malaria patients demon-
strated a consistent pattern with respect to immunoreac-
tivity of antigens with molecular weights in the range of
40 to 60 kDa. Between 40 and 60 kDa, it was identified
four main bands in the membranes that were analysed
by mass spectrometry and it was identified six immuno-
genic proteins: elongation factor-1 alpha (EF-1α), protein
disulphide isomerase (PDI); phosphoglycerate kinase
(PGK); 78 kDa glucose-regulated protein homologue
(GRP-78); rhoptry-associated protein 2 (RAP 2) and
rhoptry-associated protein 3 (RAP 3).
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